MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Ovid therapeutics Inc

Fechado

SetorSaúde

0.54 17.39

Visão Geral

Variação de preço das ações

24h

Atual

Mín

0.46

Máximo

0.56

Indicadores-chave

By Trading Economics

Rendimento

-982K

-10M

Vendas

54K

130K

Margem de lucro

-7,873.077

Funcionários

23

EBITDA

-1.8M

-12M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+489.58% upside

Dividendos

By Dow Jones

Próximos Ganhos

12 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

3.3M

28M

Abertura anterior

-16.85

Fecho anterior

0.54

Sentimento de Notícias

By Acuity

50%

50%

169 / 376 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Ovid therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de jul. de 2025, 23:34 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 de jul. de 2025, 21:14 UTC

Aquisições, Fusões, Aquisições de Empresas

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 de jul. de 2025, 21:04 UTC

Grandes Movimentos do Mercado
Aquisições, Fusões, Aquisições de Empresas

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 de jul. de 2025, 23:43 UTC

Conversa de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 de jul. de 2025, 23:42 UTC

Conversa de Mercado

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 de jul. de 2025, 22:47 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 de jul. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 de jul. de 2025, 22:46 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 de jul. de 2025, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 de jul. de 2025, 22:43 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 de jul. de 2025, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 de jul. de 2025, 22:40 UTC

Aquisições, Fusões, Aquisições de Empresas

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 de jul. de 2025, 22:30 UTC

Conversa de Mercado
Ganhos

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 de jul. de 2025, 22:20 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

17 de jul. de 2025, 22:20 UTC

Conversa de Mercado
Ganhos

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 de jul. de 2025, 22:04 UTC

Conversa de Mercado
Ganhos

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 de jul. de 2025, 22:03 UTC

Aquisições, Fusões, Aquisições de Empresas

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 de jul. de 2025, 21:58 UTC

Conversa de Mercado
Ganhos

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 de jul. de 2025, 21:57 UTC

Ganhos

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 de jul. de 2025, 21:47 UTC

Ganhos

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 de jul. de 2025, 21:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 de jul. de 2025, 21:45 UTC

Conversa de Mercado

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 de jul. de 2025, 21:38 UTC

Aquisições, Fusões, Aquisições de Empresas

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 de jul. de 2025, 21:22 UTC

Aquisições, Fusões, Aquisições de Empresas

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 de jul. de 2025, 21:05 UTC

Ganhos

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 de jul. de 2025, 21:04 UTC

Aquisições, Fusões, Aquisições de Empresas

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 de jul. de 2025, 21:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 de jul. de 2025, 20:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 de jul. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

17 de jul. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

Comparação entre Pares

Variação de preço

Ovid therapeutics Inc Previsão

Preço-alvo

By TipRanks

489.58% parte superior

Previsão para 12 meses

Média 2.83 USD  489.58%

Máximo 4 USD

Mínimo 1.5 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Ovid therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.275 / 0.33Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

169 / 376 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.